Johnson & Johnson will stop selling talcum-based baby powder globally

Johnson & Johnson will cease promoting its talcum-based child powder worldwide and substitute the product with its present cornstarch model beginning subsequent yr, the buyer merchandise large said late on Thursday.

The transfer comes after thousands of lawsuits from ladies in recent times who claimed utilizing the powder gave them both ovarian most cancers or mesothelioma, a most cancers that strikes the lungs and different organs. The corporate insists, and medical analysis on talc additionally signifies, that the infant powder is protected and would not trigger most cancers.

Johnson & Johnson determined to drag the product as a consequence of “deceptive talc litigation promoting that triggered world confusion and unfounded concern,” an organization spokeswoman mentioned.

The New Jersey firm mentioned demand for its talc powder has declined, which additionally prompted the change. Firm officers mentioned the transfer will simplify Johnson & Johnson’s product choice and meet evolving world developments.

Johnson & Johnson stopped selling its talc-based baby powder in the U.S. and Canada in 2020.

Final summer season, a gaggle of Black women filed a lawsuit in opposition to Johnson & Johnson, claiming the corporate marketed its child powder to Black ladies for many years regardless of realizing it had elements that might trigger ovarian most cancers. That lawsuit — from the Nationwide Council of Negro Girls — comes roughly three years after a Missouri courtroom ordered Johnson & Johnson to pay $4.7 billion in damages to ladies in an analogous case. That quantity was later lowered to $2.1 billion.

Johnson & Johnson knew of asbestos in baby powder, report says


Talcum is a mineral related in construction to asbestos, which is thought to trigger most cancers, and they’re generally obtained from the identical mines. 

In 2020, the corporate recalled 33,000 bottles of the infant powder after FDA regulators discovered a small quantity of asbestos in a bottle bought on-line. Later that yr, Johnson & Johnson mentioned that 15 tests of the same bottle of child powder performed by two laboratories employed by the corporate discovered no asbestos. 

A U.S. government-led analysis of 250,000 ladies, the biggest such research to have a look at the query, discovered no robust proof linking child powder with ovarian most cancers, though the lead creator of the evaluation known as the outcomes “very ambiguous.”

Final fall, the corporate created a derivative subsidiary named LTL Administration to handle all its talc lawsuit claims. LTL Management later filed for Chapter 11 bankruptcy in a transfer that some imagine was designed to delay settlements from the varied lawsuits. Johnson & Johnson mentioned it funneled about $2 billion right into a belief fund created to pay claims the chapter courtroom determines that it owes.

Johnson & Johnson additionally mentioned final fall that it will flip its client well being enterprise — which offered the infant powder, Band-Support bandages and different merchandise — right into a separate publicly traded firm. The a part of the corporate promoting prescribed drugs and medical units will preserve the J&J identify.

Shares of Johnson & Johnson fell almost 1% in early morning buying and selling Friday, to about $165 every. Nonetheless, the inventory has carried out higher than the Dow Jones Industrial Common, of which J&J is a member, for many of this yr.

The Related Press contributed to this report. 

Source by [author_name]

Leave a Reply

Your email address will not be published. Required fields are marked *